Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
RESEARCH TOOLSreports
MLTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.55 - $58.26
Previous CloseN/A
Volume45.38K
Average Volume (3M)423.08K
Market Cap
$2.68B
Enterprise Value$2.69B
Total Cash (Recent Filing)$1.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 24, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding63,282,726
10 Day Avg. Volume358,583
30 Day Avg. Volume423,081
Standard Deviation0.20
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-204.29K
Enterprise Value/Ebitda-24.79
Forecast
1Y Price Target
$79.20Price Target Upside89.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Data ReadoutsThe release of top-line data from the Phase 3 VELA program with lead candidate sonelokimab (SLK) in hidradenitis suppurativa (HS) may position SLK as a best-in-class therapy for HS patients.
Financial PositionThe company expects its cash, cash equivalents, and short-term marketable debt securities totaling $448M to be sufficient to fund operations through at least the end of 2026.
Bears Say
Financial PerformanceMoonLake recorded a full-year 2024 net loss of $1.89 per share, which is slightly higher than the forecasted net loss of $1.84 per share.
---
Ownership Overview
25.92% Insiders
15.86% Mutual Funds
0.13% Other Institutional Investors
57.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $37.55 and its highest was $58.26 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $2.68B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Mar 24, 2025 which is in 21 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Nov 07, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.125.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.62.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,282,726 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -1.573%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
---
MoonLake Immunotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.20 (89.66% Upside)
$79.20 (89.66% Upside)
Blogger Sentiment
Neutral
MLTX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 71.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.49%
12-Months-Change
Fundamentals
Return on Equity
-25.24%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
Helix Acquisition Corp is a blank check company.
---
MLTX Stock 12 Month Forecast
Average Price Target
$79.20
▲(89.66% Upside)
Technical Analysis
AnaptysBio
―
Kiniksa Pharmaceuticals
―
RAPT Therapeutics
―
Immunovant
―
Beam Therapeutics
―
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
9/19 ratings generated profit
1 Year Average Return
+101.86%
reiterated a buy rating 5 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +101.86% per trade.
---